Patents by Inventor Robert C. Ladner

Robert C. Ladner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention and reduction of blood loss
    Patent number: 7851442
    Abstract: Kits containing a dry lyophilized kallikrein inhibitor are described.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 14, 2010
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley
  • METALLOPROTEINASE-BINDING PROTEINS
    Publication number: 20100291001
    Abstract: Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: November 18, 2010
    Applicant: DYAX CORP.
    Inventors: DANIEL T. DRANSFIELD, KRISTIN ROOKEY, ROBERT C. LADNER
  • PLASMIN-INHIBITORY THERAPIES
    Publication number: 20100286061
    Abstract: The disclosure features a method of treating cancers, angiogenesis-related disorders and lymphangiogenesis-related disorders with plasmin inhibitors. An exemplary method includes: administering, to a subject, a plasmin inhibitor, such as a protein that includes a Kunitz domain that inhibits plasmin.
    Type: Application
    Filed: November 23, 2009
    Publication date: November 11, 2010
    Inventors: Laetitia DEVY, Arthur C. LEY, Robert C. LADNER
  • Metalloproteinase Binding Proteins
    Publication number: 20100266490
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Application
    Filed: May 7, 2010
    Publication date: October 21, 2010
    Applicant: DYAX CORP.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Prevention and reduction of blood loss
    Patent number: 7811991
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 12, 2010
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley
  • Antibodies that bind MMP-14
    Patent number: 7745587
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: June 29, 2010
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Nucleic acids encoding polypeptide inhibitors of human plasmin derived from the Kunitz domains
    Patent number: 7736867
    Abstract: This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of such proteins in therapeutic, diagnostic, and clinical methods.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: June 15, 2010
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Kallikrein-inhibitor therapies
    Patent number: 7704949
    Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: April 27, 2010
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams, Maria Grazia Simoni, Luigi Bergamaschini
  • KALLIKREIN-INHIBITOR THERAPIES
    Publication number: 20100034805
    Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 11, 2010
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
    Publication number: 20100003195
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Application
    Filed: June 8, 2009
    Publication date: January 7, 2010
    Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert C. Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski
  • Kallikrein-binding “Kunitz domain” proteins and analogues thereof
    Patent number: 7628983
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: December 8, 2009
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
    Publication number: 20090264350
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: May 18, 2007
    Publication date: October 22, 2009
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-thrombolytic Agents and Uses Thereof
    Publication number: 20090247453
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 1, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof
    Publication number: 20090234009
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 17, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof
    Publication number: 20090233852
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 17, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof
    Publication number: 20090227495
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 10, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof
    Publication number: 20090227494
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 10, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof
    Publication number: 20090221480
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 3, 2009
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • METHODS FOR PRODUCING SPECIFIC BINDING PAIRS
    Publication number: 20090215119
    Abstract: Provided are improved methods for providing specific binding pairs (SBPs). The methods enable production of libraries of SBP members using both a large population of one member of the SBPs and a smaller, preselected population of the other member of the SBPs having affinity for a preselected target.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 27, 2009
    Applicant: DYAX CORP.
    Inventor: Robert C. Ladner
  • Poly-pegylated protease inhibitors
    Patent number: 7550427
    Abstract: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: June 23, 2009
    Assignee: Dyax Corp.
    Inventors: Arthur C. Ley, Aaron K Sato, Robert C. Ladner, Mark Stochl